CA2547196A1 - Combinaison de (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation - Google Patents

Combinaison de (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation Download PDF

Info

Publication number
CA2547196A1
CA2547196A1 CA002547196A CA2547196A CA2547196A1 CA 2547196 A1 CA2547196 A1 CA 2547196A1 CA 002547196 A CA002547196 A CA 002547196A CA 2547196 A CA2547196 A CA 2547196A CA 2547196 A1 CA2547196 A1 CA 2547196A1
Authority
CA
Canada
Prior art keywords
combination
leukemia
methyl
imatinib
proliferative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002547196A
Other languages
English (en)
Inventor
Tim H. Bruemmendorf
Stefan Balabanov
Ulrike Hartmann
Winfried Kammer
Alfred Nordheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2547196A1 publication Critical patent/CA2547196A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002547196A 2003-12-19 2004-12-17 Combinaison de (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation Abandoned CA2547196A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19
US60/531,563 2003-12-19
PCT/EP2004/014439 WO2005058320A1 (fr) 2003-12-19 2004-12-17 Combinaison de (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation

Publications (1)

Publication Number Publication Date
CA2547196A1 true CA2547196A1 (fr) 2005-06-30

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002547196A Abandoned CA2547196A1 (fr) 2003-12-19 2004-12-17 Combinaison de (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation

Country Status (17)

Country Link
US (1) US20080139480A1 (fr)
EP (1) EP1696917A1 (fr)
JP (1) JP2007514699A (fr)
KR (1) KR20060125810A (fr)
CN (1) CN1889952A (fr)
AU (2) AU2004298761A1 (fr)
BR (1) BRPI0417759A (fr)
CA (1) CA2547196A1 (fr)
EC (1) ECSP066656A (fr)
IL (1) IL176070A0 (fr)
MA (1) MA28240A1 (fr)
MX (1) MXPA06006925A (fr)
NO (1) NO20063326L (fr)
RU (1) RU2006125741A (fr)
TN (1) TNSN06182A1 (fr)
WO (1) WO2005058320A1 (fr)
ZA (1) ZA200603904B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402041T3 (es) 2007-08-31 2013-04-26 Janssen Pharmaceutica, N.V. Combinaciones de imazalil e hidroxipiridonas
WO2009036753A2 (fr) * 2007-09-20 2009-03-26 Schebo Biotech Ag Nouveaux produits pharmaceutiques, procédés de fabrication de ceux-ci et utilisation de ceux-ci en thérapie médicale
CN101932243B (zh) 2008-02-06 2014-04-23 詹森药业有限公司 苯基吡咯和吡啶酮*化合物的组合
EP2242365B1 (fr) * 2008-02-06 2013-01-16 Janssen Pharmaceutica NV Combinaisons de pyrimethanil et de composes de pyrion
WO2010048712A1 (fr) * 2008-10-31 2010-05-06 University Health Network Ciclopirox et cytarabine pour le traitement de troubles leucémiques
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
AU2011261501B2 (en) * 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
AU2011263720B2 (en) 2010-06-10 2013-11-07 Janssen Pharmaceutica Nv Combinations of pyrimethanil and monoterpenes
EP2587920B1 (fr) 2010-07-01 2016-08-10 Janssen Pharmaceutica, N.V. Combinaisons antimicrobiennes des composes de pyrion avec des polyéthylèneimines
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (fr) * 1985-11-25 1987-07-01 The Hospital For Sick Children Application d'agents chélatants
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
ES2331562T3 (es) * 2001-03-23 2010-01-08 Enzon, Inc. Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.
WO2004007676A2 (fr) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Therapie combinee servant a traiter des tumeurs

Also Published As

Publication number Publication date
WO2005058320A1 (fr) 2005-06-30
ECSP066656A (es) 2006-10-25
CN1889952A (zh) 2007-01-03
RU2006125741A (ru) 2008-01-27
TNSN06182A1 (en) 2007-11-15
MXPA06006925A (es) 2006-08-23
AU2004298761A1 (en) 2005-06-30
IL176070A0 (en) 2006-10-05
NO20063326L (no) 2006-09-19
KR20060125810A (ko) 2006-12-06
US20080139480A1 (en) 2008-06-12
BRPI0417759A (pt) 2007-04-10
AU2009201694A1 (en) 2009-05-28
MA28240A1 (fr) 2006-10-02
ZA200603904B (en) 2007-09-26
EP1696917A1 (fr) 2006-09-06
JP2007514699A (ja) 2007-06-07

Similar Documents

Publication Publication Date Title
AU2009201694A1 (en) Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
Cicenas et al. Roscovitine in cancer and other diseases
JP6532878B2 (ja) 組合せ医薬
US11938124B2 (en) Combination therapy for treatment of cancer
EP1250140B1 (fr) Combinaison d'un inhibiteur de abl-, pdgf-recepteur- et/ou kit recepteur-tyrosine kinase et d'un compose organique capable de se lier a une glycoproteine alpha1-acide
US11045443B2 (en) Glutaminase inhibitor therapy
US20190134056A1 (en) K-ras mutations and antagonists
JP7370599B2 (ja) 老化細胞のためのバイオマーカー
WO2013152342A1 (fr) Inhibiteur de mtor anticancéreux et combinaison anti-androgène
JP2008542253A (ja) Ｄｎａ損傷癌療法に対してａｔｍ欠損癌を感作するためのｄｎａ−ｐｋ阻害の使用
US20060111365A1 (en) Combinations comprising N- {5-[4- [4-methy L-piperazino-methyl) -benzoylamido] -2-methylphenyl) -4- (3-pyridyl) -2-pyrimidine-amine and at least one telomerase inhibitor
US20190000850A1 (en) Combination cancer therapy
AU2019341683A1 (en) Combinations of TGFβ inhibitors and CDK inhibitors for the treatment of breast cancer
US20220098196A1 (en) Trapping-free parp inhibitors
JP2009504674A (ja) 有機化合物の組合せ
JP2022518974A (ja) ブルトン型チロシンキナーゼ阻害剤の投薬
Ahmad et al. Venetoclax (Venclexta): A BCL‐2 Antagonist for Treating Chronic Lymphocytic Leukemia
US20230321102A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
US20240293557A1 (en) Proteolysis targeting chimeras and methods of use thereof
Riches et al. Srt1720 activator

Legal Events

Date Code Title Description
FZDE Discontinued